CLAIMS

1. Use of an antagonist of a Programmed Death 1 protein (PD-1) in combination with an IDO1 inhibitor in the manufacture of a medicament for treating a cancer in an individual, wherein the PD-1 antagonist is a monoclonal antibody with a heavy chain having the amino acid sequence of SEQ ID No: 21 and a light chain having the amino acid sequence of SEQ ID NO: 22; and the IDO1 inhibitor is 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the cancer is a solid tumor.

3. The use according to claim 1, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).

4. The use according to claim 1, wherein the cancer or tumor is selected from non-small-cell lung cancer (NSCLC), melanoma, transitional cell cancer of the bladder (TCC), renal cell cancer (RCC), triple negative breast cancer, adenocarcinoma of the endometrium, or squamous cell carcinoma of the head and neck.

5. The use according to claim 4, wherein the cancer is advanced renal cell carcinoma.

6. The use according to any one of claims 1 to 4, wherein the PD- 1 antagonist is formulated as a liquid medicament which comprises 25 mg/ml MK-3475, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5.

7. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 2 mg/kg and the IDO inhibitor is to be administered to the subject at a dose of 25 mg or 50 mg.

8. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 200 mg and the IDO inhibitor is to be administered to the subject at a dose of 25 mg or 50 mg.

9. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 2 mg/kg and the IDO inhibitor is to be administered to the subject at a dose of 25 mg.

10. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 2 mg/kg and the IDO inhibitor is to be administered to the subject at a dose of 50 mg.

11. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 200 mg and the IDO inhibitor is to be administered to the subject at a dose of 25 mg.

12. The use according to any one of claims 1 to 5, wherein the PD-1 antagonist is to be administered to a subject in need in an amount of 200 mg and the IDO inhibitor is to be administered to the subject at a dose of 50 mg.

13. The use according to any one of claims 1 to 8, wherein the IDO inhibitor is to be administered to the subject at a dose of 25 mg BID.

14. The use according to any one of claims 1 to 8, wherein the IDO inhibitor is to be administered to the subject at a dose of 50 mg BID.

15. The use according to any one of claims 1 to 8, wherein the PD-1 antagonist is to be administered every three weeks and one dose of the IDO inhibitor is to be administered two times per day.